Combination treatment for solid tumors that stopped responding to prior therapy
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (PIN plus an anti-PD1 immunotherapy) for people with advanced solid tumors that either did not respond to standard treatment or have tumor types known to have low response to immunotherapy, like liver cancer. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic solid tumor that has not responded to at least one prior treatment, or there is no standard first-line therapy for your cancer type.
- Your tumor has shown resistance, no response, or low response to prior anti-PD-1/PD-L1 immunotherapy (for example, liver cancer).
- You have at least one tumor that can be measured on scans and one tumor that can be injected directly (at least 1 cm wide).
- You are willing to have a new tumor biopsy during the study.
- Your kidney, liver, and blood cell counts are within acceptable ranges, and your heart function is normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
This trial tests a combination of two drugs—an injection directly into liver tumors (PIN) plus an immunotherapy (Sintilimab) given through a vein—for people with advanced colorectal cancer that has spread to the liver and has not gotten better after at least two prior treatments.
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
This trial tests a new two-drug combination (BM230 plus a PD-1 inhibitor) for people with advanced cancers that have certain HER2 changes. It's for those whose cancer has grown after standard treatments, and aims to see if the combination is safe and slows cancer progression.
This early-phase study tests an anti–PD-1 antibody, either alone or with decitabine or chemotherapy, in people whose cancer has come back or isn’t responding to treatment. It may help your immune system attack the cancer, especially after prior therapies.
This trial tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and whether it can shrink tumors or slow their growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.